101. Salter osteotomy has lower fluoroscopy exposure time compared to Tonnis lateral acetabuloplasty.
- Author
-
Sevencan A, Akpinar E, Ucpunar H, Akbulut D, Ozyalvac ON, and Bayhan AI
- Subjects
- Male, Female, Humans, Fluoroscopy, Osteotomy methods, Treatment Outcome, Retrospective Studies, Acetabulum diagnostic imaging, Acetabulum surgery, Acetabuloplasty, Hip Dislocation, Congenital diagnostic imaging, Hip Dislocation, Congenital surgery, Hip Dislocation surgery
- Abstract
Salter osteotomy and Tonnis lateral acetabuloplasty (TLA) are pelvic osteotomies with similar indications and clinical results used in the treatment of developmental dysplasia of the hip (DDH). The aim of our study was to compare the intraoperative fluoroscopy exposure time (FET) in patients with DDH treated with the Salter osteotomy and TLA. In this study, data were collected prospectively and compared after the study was completed. The patients were evaluated in three groups: pelvic osteotomy (group 1), open reduction with pelvic osteotomy (group 2) and open reduction + pelvic osteotomy + femoral shortening (group 3). Pelvic osteotomy techniques in each group were further analyzed in two subgroups as Salter osteotomy and TLA. Age, sex, surgery side, degree of dysplasia according to the Tönnis classification, duration of anesthesia and intraoperative FET (seconds) were recorded. A total of 109 patients (93 girls and 16 boys) were included in the study; 29 patients in group 1, 50 in group 2 and 30 in group 3. Although the patients who underwent Salter osteotomy and TLA were similar in all three groups in terms of age, sex, surgery side, Tönnis classification and duration of anesthesia, FET was longer in the patients who underwent TLA (group 1, P < 0.001; group 2, P < 0.001; group 3, P = 0.005). The use of the Salter osteotomy technique in the treatment of acetabular dysplasia in patients with DDH seems to be more advantageous in terms of FET than TLA osteotomy. It would be beneficial to consider this result in terms of radiation safety. Level of Evidence: II., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF